Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

PD-L1 as a prognostic biomarker in surgically resectable non- small cell lung cancer: a meta-analysis
Stephanie Tuminello, Daniel Sikavi, Rajwanth Veluswamy, et al.
Translational Lung Cancer Research (2020) Vol. 9, Iss. 4, pp. 1343-1360
Open Access | Times Cited: 38

Showing 1-25 of 38 citing articles:

PD-L1 expression and Tumor mutation burden as Pathological response biomarkers of Neoadjuvant immunotherapy for Early-stage Non-small cell lung cancer: A systematic review and meta-analysis
Hongsheng Deng, Yi Zhao, Xiuyu Cai, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 170, pp. 103582-103582
Closed Access | Times Cited: 65
Reliable Detection of Extracellular PD-L1 by DNA Computation-Mediated Microfluidics
Yuqian Zhang, Qiuyue Wu, Yihao Huang, et al.
Analytical Chemistry (2023) Vol. 95, Iss. 24, pp. 9373-9379
Closed Access | Times Cited: 18
Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives
Eugenia Cella, Lodovica Zullo, Silvia Marconi, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 10, pp. 1259-1273
Closed Access | Times Cited: 20
Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics
Wenjie Liu, Gengwei Huo, Peng Chen
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 11
Infective Complications of Endobronchial Ultrasound-Transbronchial Needle Aspiration (EBUS-TBNA) and Clinical Biomarkers: A Concise Review
Pinelopi Bosgana, Dimitrios Ampazis, Vasileios Vlachakos, et al.
Diagnostics (2025) Vol. 15, Iss. 2, pp. 145-145
Open Access
EGFR mutation status affects intra-tumoural heterogeneity of PD-L1 expression but not agreement between assays in resectable non-small cell lung cancer
Stephanie P.L. Saw, Angela Takano, Siqin Zhou, et al.
Lung Cancer (2025) Vol. 202, pp. 108463-108463
Open Access
Efficacy and safety of immunotherapy plus chemotherapy in advanced or metastatic pulmonary large-cell neuroendocrine carcinoma
Ruyue Li, H. Zhang, Ying Li, et al.
Discover Oncology (2025) Vol. 16, Iss. 1
Open Access
PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer
Stephanie P.L. Saw, Win Pin Ng, Siqin Zhou, et al.
European Journal of Cancer (2022) Vol. 178, pp. 139-149
Open Access | Times Cited: 14
PD-(L)1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer Patients with High PD-L1 Expression: A Network Meta-Analysis
Margarita Majem, Manuel Cobo, Dolores Isla, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 7, pp. 1365-1365
Open Access | Times Cited: 19
Prognostic Impact of PD-L1 Expression in pN1 NSCLC: A Retrospective Single-Center Analysis
Florian Eichhorn, Mark Kriegsmann, Laura V. Klotz, et al.
Cancers (2021) Vol. 13, Iss. 9, pp. 2046-2046
Open Access | Times Cited: 18
Effect of Radio-Chemotherapy on PD-L1 Immunohistochemical Expression in Head and Neck Squamous Cell Carcinoma
Ilaria Girolami, Stefano Marletta, Vincenzo Fiorentino, et al.
Journal of Personalized Medicine (2023) Vol. 13, Iss. 2, pp. 363-363
Open Access | Times Cited: 7
PD-L1 Expression in Non-Small Cell Lung Cancer Specimens: Association with Clinicopathological Factors and Molecular Alterations
Mohammed S. I. Mansour, Karina Malmros, Ulrich Mager, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 9, pp. 4517-4517
Open Access | Times Cited: 11
A Real-World Systematic Analysis of Driver Mutations’ Prevalence in Early- and Advanced-Stage NSCLC: Implications for Targeted Therapies in the Adjuvant Setting
Irene Terrenato, Cristiana Ercolani, Anna Di Benedetto, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2971-2971
Open Access | Times Cited: 11
Dual-Recognition-Mediated Autocatalytic Amplification Assay for the Subpopulations of PD-L1 Positive Extracellular Vesicle
Yongan Ren, Ke Ge, QiaoQiao Tang, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 23, pp. 9585-9592
Closed Access | Times Cited: 2
The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types
Hampus Nobin, Stina Garvin, Helga Hagman, et al.
BMC Cancer (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
PD-L1 Expression and Comprehensive Molecular Profiling Predict Survival in Nonsmall Cell Lung Cancer: A Real-World Study of a Large Chinese Cohort
Yan Jin, Qianqian Xue, Xuxia Shen, et al.
Clinical Lung Cancer (2021) Vol. 23, Iss. 1, pp. 43-51
Closed Access | Times Cited: 15
Prognostic and predictive value of PD-L1 expression and tumour infiltrating lymphocytes (TiLs) in locally advanced NSCLC treated with simultaneous radiochemotherapy in the randomized, multicenter, phase III German Intergroup lung Trial (GILT)
Amanda Tufman, Jens Neumann, Farkhad Manapov, et al.
Lung Cancer (2021) Vol. 160, pp. 17-27
Closed Access | Times Cited: 13
The combination of PD-L1 expression and the neutrophil-to-lymphocyte ratio as a prognostic factor of postoperative recurrence in non-small-cell lung cancer: a retrospective cohort study
Hironobu Samejima, Kensuke Kojima, Ayako Fujiwara, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 5
A Machine Learning Approach Using PET/CT-based Radiomics for Prediction of PD-L1 Expression in Non-small Cell Lung Cancer
Chae Hong Lim, Young Wha Koh, Seung Hyup Hyun, et al.
Anticancer Research (2022) Vol. 42, Iss. 12, pp. 5875-5884
Open Access | Times Cited: 8
Evaluation of the potential herb-drug interaction between Bojungikki-tang and PD-L1 immunotherapy in a syngeneic mouse model
Sung‐yoon Yang, Jin-Mu Yi, Jaemoo Chun, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
PD‐L1 expression in patients with non‐small‐cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population
Pavla Sarova, B. Mosleh, Sonja Zehetmayer, et al.
Thoracic Cancer (2024) Vol. 15, Iss. 20, pp. 1598-1606
Open Access | Times Cited: 1
Higher tumor mutational burden and PD-L1 expression correlate with shorter survival in hematologic malignancies
Ah‐Reum Jeong, Aaron Trando, Sean D. Thomas, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Temporal Effect on PD‐L1 Detection and Novel Insights Into Its Clinical Implications in Non–Small Cell Lung Cancer
Gopal P. Pathak, Rashmi R. Shah, Mathieu Castonguay, et al.
Cancer Medicine (2024) Vol. 13, Iss. 19
Open Access | Times Cited: 1
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
Magdalena Kędzierska, Magdalena Bańkosz
Journal of Clinical Medicine (2024) Vol. 13, Iss. 23, pp. 7131-7131
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top